Authors: S. C. Ramos, M. J. Macfarlane and G. Polton
|
||||||
Résumé, analyse et commentaires |
||||||
Aucun.
|
||||||
Photo |
||||||
Aucune.
|
||||||
Analysis |
||||||
None.
|
||||||
Abstract |
Source |
|
|
|||
BACKGROUND: Epitheliotropic lymphoma is an uncommon cutaneous malignancy of T lymphocytes. Limited information is available regarding the treatment and outcome of dogs with this disease. OBJECTIVES: To evaluate the treatment outcome and toxicity profile of isotretinoin in dogs with epitheliotropic lymphoma. ANIMALS: Twelve dogs with a diagnosis of epitheliotropic lymphoma were included. MATERIALS AND METHODS: A medical database was searched for dogs diagnosed with epitheliotropic lymphoma and treated with isotretinoin between 2010 and 2021. Diagnosis, treatment details and tumour response were recorded for 12 dogs. RESULTS: All lesions resolved in four of 12 (33%) treated dogs. Lesions visibly improved in a further three dogs, giving a response rate of 58%. Two dogs' lesions remained unchanged and three progressed despite therapy. Adverse effects occurred in three dogs (25%), all of which were rapidly resolving or not affecting quality of life. CONCLUSION: Isotretinoin treatment was a well-tolerated and effective treatment for canine epitheliotropic lymphoma.
|